BioNexus Gene Lab Corp. (BGLC)
NASDAQ: BGLC
· Real-Time Price · USD
5.65
-0.35 (-5.83%)
At close: Sep 26, 2025, 3:59 PM
5.73
1.42%
After-hours: Sep 26, 2025, 07:23 PM EDT
BioNexus Gene Lab Revenue Breakdown
| Period Ending | Jun 30, 2025 |
|---|---|
| Product And Service Revenue | 2.26M |
| Product And Service Revenue Growth | n/a |
Revenue by Geography
| Period Ending | Jun 30, 2025 | Mar 31, 2025 |
|---|---|---|
| Malaysia Revenue | 1.83M | 34.22K |
| Malaysia Revenue Growth | +5248.93% | n/a |
| Singapore Revenue | 97.62K | 146.1K |
| Singapore Revenue Growth | -33.18% | n/a |
| Sri Lanka Revenue | 109.37K | n/a |
| Sri Lanka Revenue Growth | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 1.13M | -148.82K | 469.4K | 2.13M | 759.66K | 625.77K | -15.91K | 3.08M | 807.08K | 536.87K | 487.86K | 418.82K | 434.12K | 345.24K | 161.21K | 362.31K | 378.05K | 302.85K | 1.17M | 70.66K | 58.18K | 38.85K | 135.83K | 63.1K | 81.22K | 76.49K | 58.42K | 79.03K | 67.89K | 36.59K | 123.44K |
| Selling, General, and Administrative Revenue Growth | -856.10% | -131.70% | -77.96% | +180.35% | +21.40% | -4033.42% | -100.52% | +281.76% | +50.33% | +10.05% | +16.48% | -3.52% | +25.74% | +114.15% | -55.50% | -4.16% | +24.83% | -74.01% | +1549.15% | +21.44% | +49.78% | -71.40% | +115.27% | -22.32% | +6.19% | +30.93% | -26.07% | +16.40% | +85.56% | -70.36% | n/a |
| Research and Development Revenue | 12.56K | 12.14K | 47.51K | n/a | 8.2K | n/a | 54.98K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Research and Development Revenue Growth | +3.44% | -74.45% | n/a | -100.00% | n/a | -100.00% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Sales and Marketing Revenue | 608.43K | -540.7K | 2.03M | n/a | n/a | 153.87K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Sales and Marketing Revenue Growth | -212.53% | -126.63% | n/a | n/a | -100.00% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |